Neurocrine to buy Soleno Therapeutics for $2.9 billion

In this article SLNO NBIX Follow your favorite stocks CREATE FREE ACCOUNT Piotr Swiat | Lightrocket | Getty Images Neurocrine Biosciences will acquire rare disease drugmaker ⁠ Soleno Therapeutics for $2.9 billion in ​cash, the ​companies ​said on Monday, marking the neuroscience-focused drugmaker's expansion into metabolic disorders. Neurocrine ⁠has ‌offered $53 per Soleno share ⁠held, which represents a premium of about 34% to the stock's last close. Soleno ‌shares, which had risen more than 30% ​in premarket trading after the Financial Times first reported the news, were halted. The ⁠deal gives Neurocrine access to ‌Vykat XR, the first ‌drug approved in the U.S. to treat hyperphagia associated with Prader-Willi ⁠syndrome, a rare genetic disorder. Hyperphagia, ⁠or feelings of ⁠intense and persistent hunger, is the hallmark symptom of Prader-Willi ​syndrome ‌and can lead to severe obesity as well as physical, mental and behavioural problems. Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news. Subscribe to CNBC PRO Subscribe to Investing Club Licensing & Reprints CNBC Councils Select Personal Finance Join the CNBC Panel Closed Captioning Digital Products News Releases Internships Corrections About CNBC Site Map Podcasts Careers Help Contact News Tips Got a confidential news tip? We want to hear from you. Get In Touch CNBC Newsletters Sign up for free newsletters and get more CNBC delivered to your inbox Sign Up Now Get this delivered to your inbox, and more info about our products and services. Advertise With Us Please Contact Us Ad Choices Privacy Policy Your Privacy Choices CA Notice Terms of Service © 2026 Versant Media, LLC. All Rights Reserved. A Versant Media Company. Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Market Data Terms of Use and Disclaimers Data also provided by